Fibrocell Science to Report First Quarter 2014 Financial and Operating Results, and Host Conference Call and Webcast on May 19,

  Fibrocell Science to Report First Quarter 2014 Financial and Operating
  Results, and Host Conference Call and Webcast on May 19, 2014

Business Wire

EXTON, Pa. -- May 16, 2014

Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company
primarily focused on developing first-in-class treatments for rare and serious
skin and connective tissue diseases with high unmet medical needs, today
announced that it will report first quarter 2014 financial and operating
results and provide an update on May 19, 2014.The update will include its
collaboration with Intrexon Corporation (NYSE:XON). David Pernock, chairman
and chief executive officer ofFibrocell Science,will host the conference
call and webcast at5 p.m. EDT,May 19, 2014.

The conference call may be accessed by dialing 855-877-0343 for domestic
callers and 678-509-8772 for international callers. Please specify to the
operator that you would like to join the "Fibrocell Science First Quarter 2014
Financial Results Call, conference ID#: 47692611." The conference call will be
webcast live under the investor relations section ofFibrocell's website at
www.fibrocellscience.com, and will be archived there for 90 days following the
call. Please visitFibrocell's website several minutes prior to the start of
the broadcast to ensure adequate time for any software download that may be
necessary.

About Fibrocell Science, Inc.

Fibrocell Science, Inc. (NYSE MKT:FCSC) is an autologous cell therapy company
primarily focused on developing first-in-class treatments for rare and serious
skin and connective tissue diseases with high unmet medical needs. Based on
its proprietary autologous fibroblast technology, Fibrocell is pursuing
breakthrough medical applications of azficel-T for restrictive burn scarring
and vocal cord scarring. The company’s collaboration with Intrexon Corporation
(NYSE:XON), a leader in synthetic biology, includes using genetically-modified
fibroblasts for treating orphan skin diseases for which there are no currently
approved products. Fibrocell’s collaboration with UCLA—focusing on
skin-derived stem cells and more efficient ways to convert skin cells to other
cell types—holds potential for future discovery and development of autologous
cellular therapeutics. For additional information, visit
www.fibrocellscience.com.

Contact:

Investor Relations:
S.A. Noonan Communications, LLC
Susan Noonan, 212-966-3650
susan@sanoonan.com
 
Press spacebar to pause and continue. Press esc to stop.